Press release summary
CellCarta and Imagene AI expanded their collaboration on Oct. 1 to develop, validate and deploy artificial-intelligence biomarker and companion-diagnostic programs. The companies said they are already working with two unnamed pharmaceutical companies, though they did not disclose study designs, timelines or commercial terms.
The work includes an AI-enabled immunohistochemistry companion diagnostic and a Lung Prediction Panel for non-small cell lung cancer. The lung panel is currently described as a research-use-only product. CellCarta plans to bring its clinical-trial testing and CAP- and CLIA-accredited laboratory network to the collaboration, while Imagene AI supplies image-analysis models intended to identify biomarker patterns from pathology data.
Why it matters for laboratories
AI-based biomarkers can move beyond exploratory research only when models, specimen handling, assays and interpretation remain reproducible across sites and patient populations. Combining an algorithm developer with a regulated laboratory network may help address analytical validation, trial deployment and regulatory documentation for companion diagnostics. However, the announcement provides limited technical evidence. Pathology and clinical-trial laboratories should look for peer-reviewed performance data, locked-model validation, bias assessments and clear regulatory status before treating the tools as clinically actionable.
Original source: CellCarta announcement.






Leave a Reply